Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader-Willi syndrome.

What Was Tested

This phase 3 clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

This study explored the time effect on psychomotor development, anthropometric indexes, and safety for infants and young children with PWS.

Who Took Part

PubMed indexes the participants as infants, young children and children.

Motor development was measured using Peabody Developmental Motor Scales-second edition, mental development using Griffiths Development Scales-Chinese (GDS-C).

How the Study Was Run

The researchers set it up as a multicenter study.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

A phase 3, single-arm, multicenter, self-controlled study was conducted in six sites.

Height standard deviation score (SDS), body weight SDS, and body mass index (BMI) SDS were also assessed.

What Was Measured

Topics PubMed links to this paper include Anthropometry, Body Mass Index, Human Growth Hormone, Prader-Willi Syndrome and Recombinant Proteins.

The authors tagged it with the keywords Mental development, Motor development and Prader–Willi syndrome.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (World journal of pediatrics : WJP), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.